CompletedNot Applicable

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Japan451 participantsStarted 2020-10-28

Plain-language summary

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

Who can participate

Age range99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients prescribed Mayzent for prevention of relapses and delay of progression of physical disability in secondary progressive multiple sclerosis Exclusion Criteria: \-

What they're measuring

Incidence of Adverse Events (AE), Serious Adverse Events (SAE) and Adverse Reactions

Timeframe: 24 months

Trial details

NCT IDNCT04593927

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-08-30

View on ClinicalTrials.gov More Secondary Progressive Multiple Sclerosis (SPMS) trials